What this means
This randomized, double-blind, placebo-controlled trial evaluated the effects of 90-day NMNH-Ca supplementation on blood NAD⁺ levels, blood phenotypic age, physical function, BMI, and health-related quality of life in healthy adults, together with its safety and tolerability.
A plain-English summary is on its way. Until then, this is the start of the registry's own summary.
- Status
- Completed
- Who can join
- Ages 40–65
- Where
- 2 sites
The science
- Registered title
- Evaluate the Safety, Tolerability, and Efficacy of UthPeak NMNH (Reduced β-Nicotinamide Mononucleotide Calcium Salt) in Healthy Adult Participants
- Trial ID
- NCT06889740 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Healthy Aging
- What is tested
- NMNH-Ca, Placebo
- Sponsor
- EffePharm LTD
- Ages
- 40 Years to 65 Years
- Dates
- First posted Mar 21, 2025 · updated Oct 27, 2026
Registry summary
This randomized, double-blind, placebo-controlled trial evaluated the effects of 90-day NMNH-Ca supplementation on blood NAD⁺ levels, blood phenotypic age, physical function, BMI, and health-related quality of life in healthy adults, together with its safety and tolerability.
Sites (2)
- Medstar Speciality Hospital, Bengaluru, Karnataka, India
- Vinayaka Mission's Medical College and Hospital, Kāraikāl, Puducherry, India